Bris­tol My­ers, Cel­lares sign glob­al CAR-T deal as bio­phar­ma com­pa­nies look to di­ver­si­fy man­u­fac­tur­ing part­ners 

Cel­lares has inked its first in­ter­na­tion­al deal with Bris­tol My­ers Squibb, with the cell ther­a­py man­u­fac­tur­er not­ing it is go­ing through “tremen­dous tail­winds” from the Biose­cure Act with in­creased in­ter­est from many po­ten­tial clients.

Bris­tol My­ers has re­served clin­i­cal and com­mer­cial ca­pac­i­ty for an undis­closed num­ber of CAR-T ther­a­pies at Cel­lares’ fu­ture fa­cil­i­ties in the US, EU and Japan, which are slat­ed to open in the next few years. “We’re build­ing out un­prece­dent­ed amounts of cell ther­a­py ca­pac­i­ty,” CEO Fabi­an Ger­ling­haus told End­points News in an in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER